Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Epidemiology

Clinicopathologic characteristics of leukemia in Japanese children and young adults

Abstract

The aim of this study is to clarify the clinicopathologic characteristics of adolescent leukemia in Japan by retrospective analysis. Patients with acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS), consecutively diagnosed from 1986 to 1999, were enrolled. A total of 3856 patients from 1 to 15 years of age and 1803 patients from 15 to 29 years of age were eligible for this study. Demographically, the frequency of AML found was almost constant during the teenage years, whereas the frequency of ALL gradually decreased. The relative frequency of CML and MDS apparently started to increase in patients in their late teens. The relative frequency of M3 and t(15;17) gradually increased during adolescence. Among patients aged 1 to 4 years, M7 was the most frequent FAB subtype. Among patients aged 5 to 9 years, M2 and t(8;21) was the most frequent subtype. The percentage of T cell ALL increased in patients 5 to 9 years old, reaching 31.2% in the 20- to 24-year-old age group. The percentage of patients with hyperdiploidy over 50 chromosomes was highest (17.0%) in patients aged 1 to 4 and decreased to 3.9% in the older teens. The percentage of patients with the Ph1 chromosome increased from 9.9% in teens to 30.0% in patients in their late twenties. When comparing event-free survival (EFS) rates for ALL according to age, the estimated 7-year EFS rate was highest for patients aged 1 to 9 years (65.9%) and intermediate for patients aged 10 to 15 years (48.4%). However, the EFS rate was significantly worse for patients aged 15 to 19 years (19.4%) and 20 to 29 years (17.0%) (P = 0.024). On the other hand, the EFS rate for AML decreased with increasing age, although without statistical significance. The overall survival rates are approximate among all age groups. The results of the study indicate that there are considerable variations in biologic features of leukemia between children and young adults. The prognosis for adolescent leukemia may be improved by introducing pediatric trials, which take into account the prognostic biological features.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Pui CH, Evans WE . Acute lymphoblastic leukemia N Engl J Med 1998 339: 605–615

    Article  CAS  PubMed  Google Scholar 

  2. Copelan EA, McGuire EA . The biology and treatment of acute lymphoblastic leukemia in adults Blood 1995 85: 1151–1168

    CAS  PubMed  Google Scholar 

  3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C . Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group Br J Haematol 1976 33: 451–458

    Article  CAS  PubMed  Google Scholar 

  4. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C . Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO) Br J Haematol 1991 78: 325–329

    Article  CAS  PubMed  Google Scholar 

  5. Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y, Ohara A, Ohkawa Y, Mori T, Ishimoto K, Sato T, Kaneko T, Maeda M, Koike K, Shitara T, Hoshi Y, Hosoya R, Tsunematsu Y, Bessho F, Nakazawa S, Saito T . Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood J Clin Oncol 2000 18: 1508–1516

    Article  CAS  PubMed  Google Scholar 

  6. Horibe K, Hara J, Yagi K, Tawa A, Komada Y, Oda M, Nishimura S, Ishikawa Y, Kudoh T, Ueda K, and the Japan Association of Childhood Leukemia Study . Prognostic factors for childhood acute lymphoblastic leukemia in Japan Int J Hematol 2000 72: 61–68

    CAS  PubMed  Google Scholar 

  7. Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Sakura T, Ohno R, for the Japan Adult Leukemia Study Group (JALSG) . No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group Int J Hematol 1999 70: 97–104

    CAS  PubMed  Google Scholar 

  8. Ueda T, Miyawaki S, Asou N, Kuraishi Y, Hiraoka A, Kuriyama K, Minami S, Ohshima T, Ino T, Tamura J, Kanamaru A, Nishikawa K, Tanimoto M, Oh H, Saito K, Nagata K, Naoe T, Yamada O, Urasaki Y, Sakura T, Ohno R . Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group Int J Hematol 1998 68: 279–289

    Article  CAS  PubMed  Google Scholar 

  9. Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Ohno R . Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group J Clin Oncol 1996 14: 204–213

    Article  CAS  PubMed  Google Scholar 

  10. Ishikawa Y, Ueda K . Results of national survey of adult type chronic myelogenous leukemia in children. Report for the Kouseisho Cancer Research Fund in 1997 (Chief Investigator: Tsukimoto I) 1998 115–120 (in Japanese)

  11. Manabe A, Kikuchi Y, Tsuji K, Nakahata T . Current status of treatment of childhood myelodysplastic syndrome in Japan. Report for the Kouseisho Cancer Research Fund in 1998 (Chief Investigator: Tsukimoto I) 1999 102–104 (in Japanese)

  12. Vickers M, Jackson G, Taylor P . The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation Leukemia 2000 14: 722–726

    Article  CAS  PubMed  Google Scholar 

  13. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM . High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia Blood 1996 87: 308–313

    CAS  PubMed  Google Scholar 

  14. Biondi A, Rovelli A, Cantu-Rajnoldi A, Fenu S, Basso G, Luciano A, Rondelli R, Mandelli F, Masera G, Testi AM . Acute promyelocytic leukemia in children: experience of the Italian Pediatric Hematology and Oncology Group (AIEOP) Leukemia 1994 8: 1264–1268

    CAS  PubMed  Google Scholar 

  15. Kojima S, Matsuyama T, Sato T, Horibe K, Konishi S, Tsuchida M, Hayashi Y, Kigasawa H, Akiyama Y, Okamura J, Nakahata T, Bessho F, Eguchi M, Nakazawa S, Ueda R . Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction Blood 1990 76: 2348–2353

    CAS  PubMed  Google Scholar 

  16. Windebank KP, Tefferi A, Smithson WA, Li CY, Solberg LA Jr, Priest JR, Elliott SC, de Alarcon PA, Weinblatt ME, Burgert EO Jr . Acute megakaryocytic leukemia (M7) in children Mayo Clin Proc 1989 64: 1339–1351

    Article  CAS  PubMed  Google Scholar 

  17. Vormoor J, Ritter J, Creutzig U, Boos J, Heyen P, Ludwig WD, Harbott J, Loffler H, Schellong G . Acute myelogenous leukaemia in children under 2 years – experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group Br J Cancer 1992 18: (Suppl.) S63–S67

    CAS  Google Scholar 

  18. Nakase K, Bradstock K, Sartor M, Gottlieb D, Byth K, Kita K, Shiku H, Kamada N . Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult cases Leukemia 2000 14: 163–168

    Article  CAS  PubMed  Google Scholar 

  19. Greaves MF, Colman SM, Beard ME, Bradstock K, Cabrera ME, Chen PM, Jacobs P, Lam-Po-Tang PR, MacDougall LG, Williams CK, Alexander FE . Geographical distribution of acute lymphoblastic leukaemia subtypes: second report of the collaborative group study Leukemia 1993 7: 27–34

    CAS  PubMed  Google Scholar 

  20. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G . Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party Br J Haematol 1997 96: 601–610

    Article  CAS  PubMed  Google Scholar 

  21. Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV . Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance Leukemia 1991 5: 196–199

    CAS  PubMed  Google Scholar 

  22. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, Chan GC, Pui CH, Grosveld G, Downing JR . TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis Leukemia 1995 9: 1985–1989

    CAS  PubMed  Google Scholar 

  23. Takahashi Y, Horibe K, Kiyoi H, Miyashita Y, Fukuda M, Mori H, Nozaki C, Hasegawa S, Kawabe T, Kato K, Kojima S, Matuyama T, Naoe T . Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia J Pediatr Hematol Oncol 1998 20: 190–195

    Article  CAS  PubMed  Google Scholar 

  24. Nachman J, Sather HN, Buckley JD, Gaynon PS, Steinherz PG, Tubergen DG, Lampkin BC, Hammond GD . Young adults 16–21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment Cancer 1993 71: (10 Suppl) 3377–3385

    Article  CAS  PubMed  Google Scholar 

  25. Ludwig WD, Reiter A, Loffler H, Gokbuget N, Hoelzer D, Riehm H, Thiel E . Immunophenotypic features of childhood and adult acute lymphoblastic leukemia (ALL): experience of the German Multicentre Trials ALL-BFM and GMALL Leuk Lymphoma 1994 13: (Suppl. 1) 71–76

    Article  PubMed  Google Scholar 

  26. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R . Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia Blood 1999 93: 3074–3080

    CAS  PubMed  Google Scholar 

  27. Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, Inaba J, Kato K, Kojima S, Matsuyama T . Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia Med Pediatr Oncol 1999 33: 525–529

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the investigators participating in the Koseisho Study Group for the treatment of intractable or secondary leukemia in children and the investigators in the JALSG for providing data. We also thank Ms Harada for preparing the manuscript.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horibe, K., Tsukimoto, I. & Ohno, R. Clinicopathologic characteristics of leukemia in Japanese children and young adults. Leukemia 15, 1256–1261 (2001). https://doi.org/10.1038/sj.leu.2402194

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402194

Keywords

This article is cited by

Search

Quick links